PrimeTime, welcome to the IH board, where the true longs
PrimeTime, welcome to the IH board, where the true longs actually discuss fairly and openly the real deal for RFMK.
The filing just shows the official details of the equity financing that the company received by way of doing business with the finders named in the filing.
It looks like $643k was obtained for 145.5M share issuance. The negative is that it further increases the OS from the already huge 1.3B level, but the positive is obviously the funding for immediate operations. The company was already starting out with zero debt so this adds $643k onto the balance sheet as operating cash which is great for growth. The added transparency also instills confidence because it shows that the CEO was serious about the imminent funding. The other interesting note is that the funder basically got a cost basis at about $0.0045 per share. It states in the filing that the funder is not to short sell a single share for a half a year and typically the also stipulate in the contract that the firm will attempt to at least wait for double the price for any potential exit, to capture the principle from the equity funding transaction, so just a guess but perhaps Ironhedge would wait until $0.009 before even thinking of selling a single share, not to mention any time constraints already in place.
It is a very positive development, but we longs who do not erroneously place odds on the CEO accomplishing what he had been planning to do and instead faithfully wait to see it happen already knew these kind of filings and corporate actions were going to be coming down the pipe. The 10K and everything else is coming as well, it's only a matter of time. RFMK is closest to a sure thing in the world of micro caps that I have ever seen. With this new capital on the books to be used for operations immediately the stock valuations I should think would jump rather abruptly, perhaps even as early as the next trading session or once most realize how this funding package has changed the growth path and fundamental valuations. This capital paves the way for tens of thousands of canna it's to be ordered.
Exciting times for RFMK!
Do or do not, there is no try.
$RFMK!
Rapid Fire Marketing, Inc. (RFMK) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Important Notice for Merck & Co., Inc. Investors Investors in Merck & Co., Inc. (MRK) are being encouraged to seek legal counsel as we approach a significant deadline related to a securities class action lawsuit. This timeline marks an important opportunity for purchasers of Merck's securities made between February 3, 2022, and February 3, 2025, to secure representation...
Continue Reading
Expanding Opportunities for Justice-Impacted Individuals In a significant initiative aimed at improving the lives of justice-impacted individuals, multiple states are coming together to enhance educational and workforce pathways. This collaborative effort is focused on providing necessary resources and opportunities for individuals who have faced incarceration, aiming to...
Continue Reading
Honoring Peter Murray and SawTeen See at the CTBUH 2025 Awards The Council on Tall Buildings and Urban Habitat (CTBUH) has recognized two remarkable figures in the field of architecture and structural engineering for their essential contributions to urban design. Peter Murray, co-founder of New London Architecture, and SawTeen See, a prominent structural engineer, are the...
Continue Reading
Northern Oil and Gas Options for Strategic Growth Northern Oil and Gas is actively pursuing acquisition opportunities, specifically targeting Granite Ridge Resources. Based in Minneapolis, this ambitious company has shown intent to enhance its portfolio by considering Granite Ridge, a relatively smaller player in the oil industry, skilled in extracting resources from...
Continue Reading
Invivyd Hosts Webcast to Discuss the REVOLUTION Program Invivyd, Inc. (Nasdaq: IVVD) will present a live webcast detailing its innovative REVOLUTION clinical program. This event, aimed at both investors and the public, will showcase the company’s promising monoclonal antibody, VYD2311, which serves as a vaccine alternative for COVID-19 prevention. The Overview of...
Continue Reading